UK Study Details Liquid Biopsy’s Ability to Guide Metastatic Breast Cancer Treatment

Researchers from the Institute of Cancer Research, London, and the Royal Marsden NHS Foundation Trust have presented data demonstrating that blood-based genotyping assays can accurately detect specific biomarkers and potentially be used to guide targeted treatment of metastatic breast cancer. 
The researchers used Guardant Health’s liquid biopsy assay and Bio-Rad Technologies’ droplet digital PCR (ddPCR) testing to identify errors — including mutations in the HER2, ESR1, and AKT1 genes — in circulating tumor DNA (ctDNA) that had been shed into the patients’ bloodstream. 
The researchers believe the blood-based assays are now reliable enough to be applied routinely by clinicians after receiving regulatory approval.

Source: https://www.genomeweb.com/liquid-biopsy/uk-study-details-liquid-biopsys-ability-guide-metastatic-breast-cancer-treatment